{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:06:40Z","timestamp":1775434000248,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Intrathecally administered antisense oligonucleotide tominersen aims to slow Huntington's disease progression by lowering mutant huntingtin (mHTT) protein levels. This study used non\u2010linear mixed effects population pharmacokinetic and pharmacodynamic (PKPD) modelling to characterize the relationship between tominersen concentration in cerebrospinal fluid (CSF) and CSF mHTT reduction. Additionally, the relationship between tominersen CSF exposure and changes in other CSF biomarkers was investigated to understand tominersen's pharmacodynamic profile. Finally, PKPD model simulations were conducted to inform the dose selection in the GENERATION HD2 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from four clinical studies, including 915 participants receiving placebo or tominersen doses (30\u2013120\u2009mg) every 4, 8 or 16\u2009weeks for up to 25\u2009months, were used to develop the PKPD model. The model was utilized to predict tominersen CSF exposure metrics for individual patients in the GENERATION HD1 study for the exposure\u2013response (ER) analysis and to simulate the PK and PD profiles for lower doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      An indirect\u2010response model described the relationship between tominersen CSF concentration and mHTT reduction, estimating a half\u2010maximal inhibitory concentration (IC\n                      <jats:sub>50<\/jats:sub>\n                      ) of 4.18\u2009ng\/mL. The ER analysis revealed that the highest exposure quartile showed a 54% mHTT reduction at steady state and transient elevations in biomarkers of neuroinjury and inflammation. In contrast, the lowest exposure quartile had a 24% mHTT reduction and a favourable biomarker profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The PKPD model quantitatively confirms the relationship between tominersen exposure and CSF mHTT lowering. The ER analysis suggests that lower tominersen exposure levels may offer a better benefit\u2013risk profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70367","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T10:05:22Z","timestamp":1764065122000},"page":"1145-1155","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1798-3472","authenticated-orcid":false,"given":"Yumi","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development Roche Innovation Center Basel  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna E.","family":"Silber Baumann","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development Roche Innovation Center Basel  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Bj\u00f6rnsson","sequence":"additional","affiliation":[{"name":"Pharmetheus AB  Uppsala Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Grimsey","sequence":"additional","affiliation":[{"name":"Roche Products Limited  Welwyn Garden City UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Hawellek","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development Roche Innovation Center Basel  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Anderson","sequence":"additional","affiliation":[{"name":"Georgetown University School of Medicine  Washington DC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blair R.","family":"Leavitt","sequence":"additional","affiliation":[{"name":"University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard G.","family":"Landwehrmeyer","sequence":"additional","affiliation":[{"name":"Ulm University  Ulm Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Tabrizi","sequence":"additional","affiliation":[{"name":"Queen Square Institute of Neurology University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"McColgan","sequence":"additional","affiliation":[{"name":"Roche Products Limited  Welwyn Garden City UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[{"name":"Queen Square Institute of Neurology University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Sanwald Ducray","sequence":"additional","affiliation":[{"name":"Roche Pharmaceutical Research and Early Development Roche Innovation Center Basel  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"6","key":"e_1_2_10_2_1","first-page":"1517","article-title":"Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice","volume":"54","author":"Baxter LT","year":"1994","journal-title":"Cancer Res"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750\u20101172\u20105\u201040"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.12.018"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092\u20108674(93)90585\u2010E"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.02.003"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010018\u20100058\u2010z"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102018\u2010320106"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(03)00530\u20101"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.08.025"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750\u20103639.1994.tb00838.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13719"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163479"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(20)30143\u20105"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900907"},{"key":"e_1_2_10_17_1","volume-title":"Translational Pharmacokinetic\/Pharmacodynamic (PK\/PD) Modeling Strategy to Support RG6042 Dose Selection in Huntington's Disease (HD) (S16.005)","author":"Ducray PS","year":"2019"},{"key":"e_1_2_10_18_1","article-title":"Design of an open\u2010label, adaptive multiple\u2010dose study to investigate the PK\/PD of RG6042 in CSF and plasma following intrathecal administration in patients with HD","volume":"26","author":"Ducray PS","year":"2019","journal-title":"Eur J Neurol"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","unstructured":"SchobelS PalermoG TrundellD et al.A global development program testing RG6042 an antisense oligonucleotide for the treatment of early manifest Huntington's disease. Paper presented at: European Huntington's Disease Network 2018 Plenary Meeting; September 16 2018.","DOI":"10.1136\/jnnp-2018-EHDN.262"},{"key":"e_1_2_10_20_1","unstructured":"Clinicaltrials.gov.NCT03842969. Accessed December 2024.https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03842969"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2300400"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13001"},{"key":"e_1_2_10_23_1","unstructured":"Clinicaltrials.gov.NCT05686551. Accessed December 2024."},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(22)00120\u2010X"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010023\u201032630\u20104"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010009\u20109112\u20105"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0361\u20109230(01)00599\u20108"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011970125687"},{"key":"e_1_2_10_30_1","unstructured":"JonssonEHK.Increasing the efficiency of the covariate search algorithm in the SCM.2018.https:\/\/www.page-meeting.org\/pdf_assets\/4534-page%20poster%202018%20v1.pdf"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248\u2010011\u20109255\u2010z"},{"key":"e_1_2_10_32_1","volume-title":"NONMEM User's Guides (1989\u20132014)","author":"Beal S","year":"2018"},{"key":"e_1_2_10_33_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2007"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2005.04.005"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70367","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70367","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T23:41:59Z","timestamp":1775432519000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/bcp.70367"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70367","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]}}}